Abstract
Joint academic–industrial projects supporting drug discovery are frequently pursued to deploy and benchmark cutting-edge methodical developments from academia in a real-world industrial environment at different scales. The dimensionality of tasks ranges from small molecule physicochemical property assessment over protein–ligand interaction up to statistical analyses of biological data. This way, method development and usability both benefit from insights gained at both ends, when predictiveness and readiness of novel approaches are confirmed, but the pharmaceutical drug makers get early access to novel tools for the quality of drug products and benefit of patients. Quantum–mechanical and simulation methods particularly fall into this group of methods, as they require skills and expense in their development but also significant resources in their application, thus are comparatively slowly dripping into the realm of industrial use. Nevertheless, these physics-based methods are becoming more and more useful. Starting with a general overview of these and in particular quantum–mechanical methods for drug discovery we review a decade-long and ongoing collaboration between Sanofi and the Kast group focused on the application of the embedded cluster reference interaction site model (EC-RISM), a solvation model for quantum chemistry, to study small molecule chemistry in the context of joint participation in several SAMPL (Statistical Assessment of Modeling of Proteins and Ligands) blind prediction challenges. Starting with early application to tautomer equilibria in water (SAMPL2) the methodology was further developed to allow for challenge contributions related to predictions of distribution coefficients (SAMPL5) and acidity constants (SAMPL6) over the years. Particular emphasis is put on a frequently overlooked aspect of measuring the quality of models, namely the retrospective analysis of earlier datasets and predictions in light of more recent and advanced developments. We therefore demonstrate the performance of the current methodical state of the art as developed and optimized for the SAMPL6 pKa and octanol–water log P challenges when re-applied to the earlier SAMPL5 cyclohexane-water log D and SAMPL2 tautomer equilibria datasets. Systematic improvement is not consistently found throughout despite the similarity of the problem class, i.e. protonation reactions and phase distribution. Hence, it is possible to learn about hidden bias in model assessment, as results derived from more elaborate methods do not necessarily improve quantitative agreement. This indicates the role of chance or coincidence for model development on the one hand which allows for the identification of systematic error and opportunities toward improvement and reveals possible sources of experimental uncertainty on the other. These insights are particularly useful for further academia–industry collaborations, as both partners are then enabled to optimize both the computational and experimental settings for data generation.
Highlights
Physics‐based modeling in drug discoveryDrug discovery is a multidimensional optimization journey starting off from early hit molecules with multiple liabilities to a clinical candidate with desired pharmacokinetic/1 3 Vol.:(0123456789)Journal of Computer-Aided Molecular Design (2021) 35:453–472 pharmacodynamic (PK/PD) and safety profile, which requires the parallel monitoring of different properties
Protein–ligand binding pose and affinity predictions were spun-off from SAMPL in the form of “Grand Challenges” organized by the Drug Design Data Resource (D3R) [41] while SAMPL5 was devoted to host–guest binding on the one hand [42] and—as an extraordinarily more complicated problem compared to earlier small molecule SAMPL challenges—distribution coefficients between water and cyclohexane on the other [43]
While the SAMPL5 post-submission pKa model was still based on self-consistent atomic site charges for determining the electrostatic contribution to the solute–solvent interactions, we turned to an embedded cluster reference interaction site model (EC-RISM) variant that allows for using the electrostatic potential arising from the solute’s wave function directly, i.e. formally in an exact manner
Summary
Journal of Computer-Aided Molecular Design (2021) 35:453–472 pharmacodynamic (PK/PD) and safety profile, which requires the parallel monitoring of different properties. Force field-based methods that use simple physics models for bonded and non-bonded interactions are well established for investigating conformational properties of proteins and drug-like compounds [14, 15] in drug discovery They are fast, easy to apply and provide results in a time frame that fits neatly to the requirements of design-make-test-analyze cycles used by project teams throughout industry. In the group of the authors, hybrid methods have been pioneered, embedding machine learning and time-dependent TD-DFT calculations to determine UV/vis spectral absorption descriptors of drug candidates in solution Beyond property prediction, this method was shown effective for the detection of fragmental contributions to toxicity, a key prerequisite for visualization and helpful for guiding drug optimization [33]. This emphasizes the importance of an exchange of pre-competitive data between industry and academia for method development and for measuring and assessing the predictive quality of the tools
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.